BSE Live
Feb 11, 16:01Prev. Close
884.20
Open Price
899.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 11, 15:55Prev. Close
882.50
Open Price
884.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
875.60 (94)
| Balance Sheet of Strides Pharma Science (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 92.16 | 91.90 | 90.30 | 89.79 | 89.68 | |
| Total Share Capital | 92.16 | 91.90 | 90.30 | 89.79 | 89.68 | |
| Reserves and Surplus | 2,459.67 | 2,030.69 | 2,104.86 | 2,266.99 | 2,682.26 | |
| Total Reserves and Surplus | 2,459.67 | 2,030.69 | 2,104.86 | 2,266.99 | 2,682.26 | |
| Total Shareholders Funds | 2,551.83 | 2,125.56 | 2,195.16 | 2,358.82 | 2,776.66 | |
| Minority Interest | 34.63 | -53.86 | -39.38 | 24.09 | 37.34 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 571.24 | 671.50 | 1,139.79 | 835.62 | 882.58 | |
| Deferred Tax Liabilities [Net] | 119.36 | 40.35 | 44.57 | 35.72 | 46.35 | |
| Other Long Term Liabilities | 66.21 | 85.32 | 217.55 | 245.25 | 466.34 | |
| Long Term Provisions | 113.94 | 91.63 | 73.42 | 64.28 | 67.41 | |
| Total Non-Current Liabilities | 870.74 | 888.79 | 1,475.34 | 1,180.87 | 1,462.67 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 1,224.37 | 1,743.03 | 1,634.67 | 1,956.34 | 1,023.84 | |
| Trade Payables | 1,032.50 | 851.59 | 982.34 | 1,071.52 | 1,178.62 | |
| Other Current Liabilities | 253.44 | 213.12 | 250.70 | 261.19 | 411.70 | |
| Short Term Provisions | 81.21 | 71.53 | 122.49 | 122.62 | 124.19 | |
| Total Current Liabilities | 2,591.52 | 2,879.26 | 2,990.20 | 3,411.68 | 2,738.35 | |
| Total Capital And Liabilities | 6,048.73 | 5,839.76 | 6,638.42 | 6,975.86 | 7,015.02 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 891.87 | 890.57 | 1,336.87 | 1,470.59 | 1,340.08 | |
| Intangible Assets | 460.85 | 445.10 | 460.37 | 390.13 | 398.74 | |
| Capital Work-In-Progress | 99.65 | 79.88 | 48.26 | 56.23 | 227.60 | |
| Fixed Assets | 1,559.48 | 1,497.56 | 1,948.22 | 2,151.80 | 2,186.19 | |
| Non-Current Investments | 339.71 | 196.93 | 438.96 | 540.34 | 598.00 | |
| Deferred Tax Assets [Net] | 269.13 | 267.35 | 265.03 | 215.15 | 198.22 | |
| Long Term Loans And Advances | 0.00 | 50.00 | 0.00 | 3.00 | 38.87 | |
| Other Non-Current Assets | 234.92 | 329.51 | 229.09 | 217.84 | 695.96 | |
| Total Non-Current Assets | 2,949.81 | 2,870.76 | 3,395.06 | 3,614.03 | 4,197.79 | |
| CURRENT ASSETS | ||||||
| Current Investments | 69.50 | 105.76 | 50.84 | 0.00 | 99.41 | |
| Inventories | 1,277.57 | 1,126.24 | 1,146.51 | 1,173.80 | 1,200.70 | |
| Trade Receivables | 1,202.94 | 1,141.87 | 1,299.40 | 1,207.30 | 1,106.86 | |
| Cash And Cash Equivalents | 136.78 | 191.17 | 315.96 | 187.35 | 179.77 | |
| Short Term Loans And Advances | 10.45 | 12.73 | 7.78 | 4.82 | 4.05 | |
| OtherCurrentAssets | 401.67 | 391.23 | 422.87 | 788.56 | 226.44 | |
| Total Current Assets | 3,098.91 | 2,969.00 | 3,243.36 | 3,361.83 | 2,817.23 | |
| Total Assets | 6,048.73 | 5,839.76 | 6,638.42 | 6,975.86 | 7,015.02 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 197.13 | 558.80 | 660.45 | 1,211.57 | 891.63 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 322.51 | 7.63 | 53.04 | 4.78 | 14.10 | |
| Non-Current Investments Unquoted Book Value | 6.52 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 99.41 |
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016